Russell Ross, PhD

Sorrento Therapeutics
Sandy Springs, GA, United States

Russell F. Ross is the Sofusa Chief Technical Officer at Sorrento Therapeutics and leads the development and commercialization of novel lymphatic directed therapies for rheumatoid arthritis, oncology including melanoma and cutaneous lymphomas, and other immune indications. Dr. Ross is also the inventor of the Sofusa lymphatic delivery platform redefining therapies for immune system diseases by treating targets in the lymph nodes versus more traditional systemic approaches. Prior, Dr. Ross spent 22 years at Kimberly-Clark in several research and leadership positions in both the consumer and professional B-to-B businesses. He received his doctorate from the University of Wisconsin and has been awarded more than 73 patents and published 9 peer reviewed papers.

Disclosure information not submitted.

Presentation(s):

• 1439: Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections

  Sunday, November 13, 2022
  1:00 PM – 3:00 PM Eastern Time